Genovis AB (publ.) (STO:GENO)

Market Cap	1.50B
Revenue (ttm)	131.32M
Net Income (ttm)	32.92M
Shares Out	65.47M
EPS (ttm)	0.50
PE Ratio	45.45
Forward PE	52.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,009
Average Volume	88,440
Open	22.70
Previous Close	23.10
Day's Range	22.00 - 23.60
52-Week Range	17.10 - 39.85
Beta	1.93
RSI	55.78
Earnings Date	Apr 28, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.